Cargando…
CKD After 225Ac-PSMA617 Therapy in Patients With Metastatic Prostate Cancer
Autores principales: | Pelletier, Karyne, Côté, Gabrielle, Fallah-Rad, Nazanin, John, Rohan, Kitchlu, Abhijat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938068/ https://www.ncbi.nlm.nih.gov/pubmed/33733002 http://dx.doi.org/10.1016/j.ekir.2020.12.006 |
Ejemplares similares
-
Light Chain Crystal Podocytopathy in a Patient With Systemic Indolent B-Cell Lymphoma
por: Kamar, Fareed, et al.
Publicado: (2019) -
Persistent Mixed Cryoglobulinemia Despite Successful Treatment of Hepatitis C, Aggressive B-Cell–Directed Therapies, and Long-term Plasma Exchanges
por: Pelletier, Karyne, et al.
Publicado: (2019) -
Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022) -
[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022) -
Favorable Effects of Octreotide in Congenital Chloride Diarrhea Associated With CKD
por: Hussein, Maged H., et al.
Publicado: (2022)